{"id":571907,"date":"2025-12-22T00:00:00","date_gmt":"2025-12-22T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/concon0002-2025-biopharma-non-small-cell-lung-cancer-geographic-focus-china-china-in-depth-non-small-cell-lung-cancer\/"},"modified":"2026-04-23T11:15:35","modified_gmt":"2026-04-23T11:15:35","slug":"concon0002-2026-biopharma-non-small-cell-lung-cancer-geographic-focus-china-china-in-depth-non-small-cell-lung-cancer","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/concon0002-2026-biopharma-non-small-cell-lung-cancer-geographic-focus-china-china-in-depth-non-small-cell-lung-cancer\/","title":{"rendered":"Non-Small-Cell Lung Cancer &#8211; Geographic Focus: China &#8211; China In-Depth &#8211; Non-Small-Cell Lung Cancer"},"content":{"rendered":"<p>Non-small-cell lung cancer (<abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr>) is the leading cause of cancer-related mortality in China. Treatment is based on biomarker status; patients with <abbr title=\"epidermal growth factor receptor\">EGFR<\/abbr>&#8211; and <abbr title=\"anaplastic lymphoma kinase\">ALK<\/abbr>-positive tumors generally receive tyrosine kinase inhibitors (<abbr title=\"tyrosine kinase inhibitor\">TKI<\/abbr>s); for patients without actionable biomarkers, immune checkpoint inhibitors have become the standard of care. More-efficacious therapies are needed, especially for patients who progress after immune checkpoint inhibitor treatment. The late-phase pipeline of <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr> therapies in China is diverse. In this report, we provide a comprehensive analysis of <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr> patient populations, current disease management, unmet needs, and the potential of current and emerging therapies. Understanding the impact of clinical and nonclinical factors\u2014price dynamics, inclusion in China\u2019s National Reimbursement Drug List (<abbr title=\"National Reimbursement Drug List\">NRDL<\/abbr>)\u2014will be key to the success of current and future players in this highly lucrative market.<\/p>\n<p><b>Questions answered<\/b><\/p>\n<ul class=\"round-bullets\">\n<li>What is the diagnosed incidence of <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr> in China, and how are patients with <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr> treated today? Do treatment management strategies differ between urban and rural China?<\/li>\n<li>What are interviewed experts\u2019 insights into current treatment options?<\/li>\n<li>What are the key unmet needs in the management of <abbr title=\"non-small-cell lung cancer\">NSCLC<\/abbr>?<\/li>\n<li>What are the key market access considerations, and how will they impact the uptake of emerging therapies in this market?<\/li>\n<li>What are the key drivers and constraints in this market, and how will the market evolve over the forecast period?<\/li>\n<\/ul>\n<p><strong>Product description<\/strong><\/p>\n<p>China In-Depth offers comprehensive market intelligence with world-class epidemiology, insight into the China-specific market access landscape, current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n<ul class=\"round-bullets\">\n<li>Optimize your long-term disease and development strategy in China.<\/li>\n<li>Quantify market potential for your pipeline assets and those of your competitors.<\/li>\n<li>Understand current treatment paradigms, the complex access and reimbursement environment, and the current and future therapeutic landscape.<\/li>\n<li>Gauge the commercial outlook and impact of key market events.<\/li>\n<\/ul>\n","protected":false},"template":"","class_list":["post-571907","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-non-small-cell-lung-cancer","biopharma-therapy-areas-solid-tumors","biopharma-product-china-in-depth","biopharma-geography-china","biopharma-geography-us","biopharma-date-2297"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/571907","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/571907\/revisions"}],"predecessor-version":[{"id":572133,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/571907\/revisions\/572133"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=571907"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}